459 related articles for article (PubMed ID: 26337806)
1. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
[TBL] [Abstract][Full Text] [Related]
6. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Richardson PG; Hofmeister CC; Rosenbaum CA; Htut M; Vesole DH; Berdeja JG; Liedtke M; Chari A; Smith SD; Lebovic D; Raje N; Byrne C; Liao E; Gupta N; Bacco AD; Estevam J; Berg D; Baz R
Br J Haematol; 2018 Jul; 182(2):231-244. PubMed ID: 29938772
[TBL] [Abstract][Full Text] [Related]
7. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J; Gupta N; Di Bacco A; Hui AM; Lonial S
Blood; 2014 Aug; 124(7):1038-46. PubMed ID: 24920586
[TBL] [Abstract][Full Text] [Related]
9. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Voorhees PM; Suman VJ; Tuchman SA; Laubach JP; Hassoun H; Efebera YA; Mulkey F; Bova-Solem M; Santo K; Carlisle D; McCarthy PL; Richardson PG
Am J Hematol; 2021 Dec; 96(12):1595-1603. PubMed ID: 34559902
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
[TBL] [Abstract][Full Text] [Related]
12. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Hanley MJ; Gupta N; Venkatakrishnan K; Bessudo A; Sharma S; O'Neil BH; Wang B; van de Velde H; Nemunaitis J
J Clin Pharmacol; 2018 Jan; 58(1):114-121. PubMed ID: 28783865
[TBL] [Abstract][Full Text] [Related]
14. Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Sokol J; Guman T; Chudej J; Hlebaskova M; Stecova N; Valekova L; Kucerikova M; Stasko J
Ann Hematol; 2022 Jan; 101(1):81-89. PubMed ID: 34550463
[TBL] [Abstract][Full Text] [Related]
15. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
16. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Iida S; Izumi T; Komeno T; Terui Y; Chou T; Ikeda T; Berg D; Fukunaga S; Sugiura K; Sasaki M
Int J Clin Oncol; 2022 Jan; 27(1):224-233. PubMed ID: 34599726
[TBL] [Abstract][Full Text] [Related]
17. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
[TBL] [Abstract][Full Text] [Related]
18. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
[TBL] [Abstract][Full Text] [Related]
19. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
